Patents by Inventor Tim Carlton

Tim Carlton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS
    Publication number: 20190008778
    Abstract: There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a pharmaceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.
    Type: Application
    Filed: September 25, 2018
    Publication date: January 10, 2019
    Applicant: VHSQUARED LIMITED
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Gary Whale, John Wahlich, Mike Frodsham
  • POLYPEPTIDE COMPRISING AN IMMUNOGLOBULIN CHAIN VARIABLE DOMAIN WHICH BINDS TO CLOSTRIDIUM DIFFICILE TOXIN B
    Publication number: 20180100008
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to Clostridium difficile toxin B.
    Type: Application
    Filed: September 27, 2017
    Publication date: April 12, 2018
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Nika Strokappe, Theo Verrips
  • POLYPEPTIDE COMPRISING AN IMMUNOGLOBULIN CHAIN VARIABLE DOMAIN WHICH BINDS TO CLOSTRIDIUM DIFFICILE TOXIN A
    Publication number: 20180100009
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to Clostridium difficile toxin A.
    Type: Application
    Filed: September 27, 2017
    Publication date: April 12, 2018
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Nika Strokappe, Theo Verrips
  • POLYPEPTIDES
    Publication number: 20180009881
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain comprising three complementarity determining regions (CDR1-CDR3) and four framework regions, wherein: (a) at least one lysine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue, and/or (b) at least one arginine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue; wherein the polypeptide has increased intestinal stability relative to a corresponding polypeptide not having said histidine substitutions.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 11, 2018
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton
  • Polypeptides
    Publication number: 20170002069
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to TNF-alpha, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Application
    Filed: September 22, 2016
    Publication date: January 5, 2017
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Keith Ray